Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plexus is a combination pharmaceutical product containing the mucolytic agent **ambroxol** and the first-generation antihistamine **dexchlorpheniramine maleate**. Ambroxol facilitates respiratory tract clearance by reducing mucus viscosity and stimulating surfactant production; it also exhibits local anesthetic properties through the inhibition of voltage-gated sodium channels. Dexchlorpheniramine maleate serves as a competitive antagonist at H1 histamine receptors, effectively reducing allergic symptoms such as edema, pruritus, and secretions. This combination is primarily utilized in international markets for the symptomatic treatment of respiratory conditions where both airway congestion and allergic triggers are present, such as allergic bronchitis or rhinobronchitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Plexus.